In patients with mild or moderate liver dysfunction, the initial dose of Remodulin should be decreased to 0.625 ng/kg/min ideal body weight and should be increased cautiously.
The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.